300206.SZ
理邦仪器
SZSE · Healthcare · C 制造业 · CN
CNY 11.93
−1.65%Year over year
Reported trailing growth
- Revenue
- +15.7%
- EBITDA
- —
- EBIT
- +91.5%
- EPS
- +83.2%
- Free cash flow
- +26.2%
- Operating cash flow
- +15.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.7%
- EBITDA
- +7.0%
- EBIT
- +9.0%
- Net income
- +9.5%
- EPS
- +9.5%
- Free cash flow
- -2.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026